PROCEPT BioRobotics (PRCT) Q4 2025 earnings review
A Painful, Deliberate Reset: Channel Destocking Crushes Q4 Growth
PROCEPT BioRobotics engineered a massive fundamental reset in Q4. Under new CEO Larry Wood, the company halted end-of-quarter purchasing incentives and aggressively reduced field inventory. The result was a severe deceleration in revenue growth to just 12% YoY (down from 43% in Q3). This policy shift caused a violent divergence: actual U.S. patient procedures soared 69% YoY to 12,200, while handpieces sold to hospitals grew only 7% to 9,400. This destocking event heavily impacted Q4 margins and forced a downward revision to the initial 2026 revenue guidance (from $410-$430M to $390-$410M). Management is ripping the band-aid off to align sales with real-world utilization.
🐂 Bull Case
Despite the ugly headline revenue, actual clinical utilization is thriving. U.S. procedures performed jumped 69% YoY to a record 12,200. The commercial pipeline also delivered its strongest capital quarter ever with 65 new system placements.
Eliminating discounting and end-of-quarter incentives immediately improved handpiece average selling prices (ASP) by 5% sequentially to $3,340. 2026 guidance assumes a further increase to $3,500.
🐻 Bear Case
The massive drop in handpiece volume crushed factory overhead absorption, dragging Q4 gross margins down to 61% (from 64% last year). Adjusted EBITDA loss widened dramatically to $19.0M from $10.3M.
The transition is causing more friction than previously telegraphed. 2026 revenue guidance was reset downwards to account for sales force realignment, establishing a dedicated launch team, and eliminating the historical 8-16% channel stuffing buffer.
⚖️ Verdict: 🔴
Bearish short-term, Bullish long-term. The headline numbers look disastrous compared to previous quarters of 40-50% growth, and the 2026 guidance cut will likely punish the stock. However, aligning sell-in with sell-through is a fundamentally necessary step for a maturing MedTech company.
Key Themes
Massive Inventory Destocking Shock
Decelerating violently. In Q3 2025, PROCEPT sold ~13,200 handpieces. In Q4, that plummeted to 9,400. Management admitted that historically, unit sales exceeded true procedure volumes by 8% to 16% due to par-level management and quarter-end incentives. This channel stuffing has ended, resulting in an artificial, but severe, contraction in Q4 consumable revenue growth (16% YoY vs 50%+ in prior quarters).
Capital Placements Remain Unfazed
Stable/Accelerating. While the consumable side underwent a painful reset, capital equipment demand remains incredibly strong. PROCEPT placed a record 65 systems in Q4 (up from 60 in 24Q4 and 58 in 25Q3), bringing the U.S. install base to 718. This proves hospital CAPEX budgets are still open for the HYDROS system, insulating the company from broader macro tightening concerns.
Gross Margin Reversal
Reversing. Gross margins had steadily climbed to 65% by mid-2025. In Q4, margins abruptly reversed to 61%. Management cited two culprits: a loss of overhead absorption due to the much lower handpiece production volume, and a one-time cost associated with an unspecified 'voluntary field action.' This disrupts the narrative of immediate, continuous operating leverage.
Strategic Pricing Over Volume
Accelerating. A key component of the new TAVR-style playbook is extracting maximum value per procedure rather than pushing bulk inventory. By killing quarter-end volume discounts, handpiece ASP climbed 5% sequentially to $3,340. Management intends to push this to $3,500 in 2026, offsetting the mathematical loss of selling fewer 'stuffed' handpieces.
Sales Force Realignment Disruption
In prior calls, new CEO Larry Wood warned of 'short-term disruption' from organizational changes. This came to fruition in Q4. The company completely realigned its commercial organization, creating a dedicated launch team to fix the highly variable activation times in new accounts. While healthy long-term, this reorganization explicitly contributed to resetting 2026 guidance downwards.
Other KPIs
Accelerating. Up 22% YoY from $63.4M. The increase supports commercial expansion and increased R&D funding for the WATER IV Prostate Cancer trial. Despite the revenue shortfall, management is not pulling back on critical strategic investments, leading to a significantly wider Q4 operating loss of $31.0M.
Decelerating. Growth slowed to 25% YoY, down dramatically from 53% growth in Q3 and 69% in Q2. International execution remains a secondary priority as the domestic commercial structure undergoes its massive transition.
Stable. The company's balance sheet remains a fortress. With roughly $289.5M in liquidity against an expected 2026 Adjusted EBITDA burn of $17M-$30M, PROCEPT has a massive runway to fund its commercial pivot and complete its WATER IV cancer trials without raising capital.
Guidance
Decelerating vs full-year 2025. This implies 27-33% annual growth, a steep drop from the 37% achieved in 2025, and a direct cut from the $410M-$430M preliminary look given in Q3. This cut reflects the elimination of channel stuffing and structural commercial friction.
Stable/Decelerating. True clinical utilization is guided to grow 39-48%. While lower than 2025's explosive 69% Q4 exit rate, it represents incredibly healthy, durable patient demand as the install base matures.
Accelerating vs Q4, but weak YoY. Implies just 14-19% YoY growth against Q1 2025. This proves that the destocking and reorganization friction will persist through at least the first half of 2026 before fully normalizing.
Accelerating improvement. A significant step forward from the $50.2M loss in 2025. It shows that higher handpiece ASPs ($3,500) and recovering gross margins (~65%) will allow the business to drastically improve cash generation even with lower topline revenue growth.
Key Questions
Scope of the Voluntary Field Action
Q4 gross margins were hit by a 'one-time cost associated with a voluntary field action.' Was this related to the legacy AquaBeam systems or the new HYDROS systems, and what is the specific technical issue?
Duration of Destocking
You eliminated end-of-quarter incentives and reduced par levels. Is the channel completely flushed as of December 31, or is there lingering destocking headwind baked into the Q1 guidance of 14-19% revenue growth?
Sales Force Attrition Risk
With the realignment of the commercial organization and the elimination of historical revenue-padding incentives, are you seeing any elevated turnover in your quota-carrying sales rep ranks?
Capital Systems Pipeline
U.S. systems revenue was completely flat YoY in Q4 despite record unit placements. Is the blended ASP for capital systems dropping due to mix, or are we seeing a ceiling on pricing elasticity for the HYDROS system?